Company intelligence / Profile preview

Codiak BioSciences

Cambridge, Massachusetts, United Statesglobaldata.com ↗

Ownership: Private
Employees: ~102
Development stage: Phase 2

Overview

Codiak developed a proprietary exosome engineering and manufacturing platform ("engEx") to create targeted exosome therapeutics. Lead programs included exoSTING and exoIL‑12, both reaching early clinical stages. The company demonstrated the ability to engineer exosomes with specific payloads or surface proteins for targeted delivery but did not reach late-stage clinical success before ceasing operations due to bankruptcy.

Therapeutic areas: OncologyRare DiseasesNeurologyInfectious Diseases
Modalities: Exosome-based therapeutics
Industry: Biotech

Drug pipeline

7 assets

exoSTING

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Codiak BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Codiak BioSciences.

Explore the full profile